Emergence of targeted immune therapies for systemic lupus

Expert Opinion on Emerging Drugs

Volumn 10, Issue 1, 2005, Pages 53-65

  Merrill, Joan T ^a  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

Aphaeresis; BLyS; CTLA4Ig; Drug therapy; Inosine; Systemic lupus; Toleragen

Indexed keywords

ABETIMUS; ACETYLSALICYLIC ACID; ANTIMALARIAL AGENT; AZATHIOPRINE; BELIMUMAB; BETA2 GLYCOPROTEIN 1 ANTIBODY; CORTICOSTEROID; COUMARIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; DNA ANTIBODY; EDRATIDE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INTERLEUKIN 4 ANTIBODY; LEFLUNOMIDE; LJP 1082; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY IDEC 131; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NONSTEROID ANTIINFLAMMATORY AGENT; PRASTERONE; PREDNISOLONE; PREDNISONE; RETINOID DERIVATIVE; RITUXIMAB; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACNE; ALOPECIA; AVASCULAR NECROSIS; CATARACT; CLINICAL FEATURE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; CUSHINGOID SYNDROME; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DRUG INDICATION; DRUG MARKETING; DRUG PULSE THERAPY; DRUG TARGETING; DYSLIPOPROTEINEMIA; FEMALE STERILITY; HUMAN; IMMUNOTHERAPY; INFECTION; INFLAMMATION; LEUKOPENIA; LIFE EXPECTANCY; LIPODYSTROPHY; LIVER DYSFUNCTION; LONG TERM CARE; MALE STERILITY; METABOLIC DISORDER; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OBESITY; OSTEOPOROSIS; PLASMAPHERESIS; REMISSION; REVIEW; SIDE EFFECT; STEM CELL TRANSPLANTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOEMBOLISM; TRANSAMINITIS; TREATMENT OUTCOME; WEIGHT GAIN;

DRUG DELIVERY SYSTEMS; DRUGS, INVESTIGATIONAL; HUMANS; IMMUNOTHERAPY; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 14344257286     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.10.1.53     Document Type: Review

References (102)

1. BARR SG, ZONANA-NACACH A, MAGDER LS, PETRI M: Patterns of disease activity in systemic lupus erythematosus. Arthritis Rheum. (1999) 42(12):2682-2688. A systematic study of diverse clinical patterns in SLE.
2. Trends in Deaths from Systemic Lupus Erythematosus -United States, 1979 - 1998 morbidity and mortality weekly report. (2002) 51(17): 371-374.
3. STOJANOVICH L, STOJANOVICH R, KOSTICH V, DZJOLICH E: Neuropsychiatric lupus favourable response to low dose i.v. cyclophosphamide and prednisolone (pilot study). Lupus. (2003) 12:10-15.
4. ZONANA-NACACH A, BARR SG, MAGDER LS, PETRI M: Damage in systemic lupus and its association with corticosteroids. Arthritis Rheum. (2000) 43:1801-1808.
5. FISHER DE, BICKEL WH: Corticosteroid-induced a vascular necrosis. A clinical study of seventy-seven patients. Bone Joint Surg. Am. (1971) 53:859-873.
6. BADSHAH, H, EDWARDS CJ: Intravenous pulses of methylprednisolone for systemic lupus erythematosus. Semin. Arthritis Rheum. (2003) 32:370-377.
7. TAM LS, GLADMAN DD, HALLETT DC, RAHMAN P, UROWITZ MB: Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J. Rheumatol. (2000) 27:2142-2145.
8. BORBA EF, BONFA E: Longterm beneficial effect of chloroquine diphosphate on lipoprotein profile in lupus patients with and without steroid therapy. J. Rheumatol. (2001) 28:780-785.
9. LAKSHMINARAYANAN S, WALSH S, MOHANRAJ M, ROTHFIELD N: Factors associated with low bone mineral density in female patients with systemic lupus erythematosus. J. Rheumatol. (2001) 28:102-108.
10. LEVY RA., VILELA VS, CATALOG MJ et al.: Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus (2001) 10:401-404.
11. BARDANA EJ JR, PORTER GA, PIROFSKY B, GOURLEY RT, BAYRAKCI C: Azathioprine in steroid-insensitive nephropathy. Am. J. Med. (1970) 49:789-800.
12. DRINKARD JP, STANLEY TM, DORNFELD L et al.: Azathioprine and prednisone in the treatment of adults with lupus nephritis. Clinical, histological, and immunological changes with therapy. Medicine (Baltimore) (1970) 49:411-432.
13. EL HACHMI M, JADOUL M, LEFEBVRE C, DEPRESSEUX G, HOUSSIAU FA: Relapses of lupus nephritis: incidence, risk factors, serology and impact on outcome. Lupus (2003) 12:692-696.
14. CHAN TM, LI FK, HAO WK et al.: Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression. Lupus (1999) 8:545-551.
15. CONTRERAS G, PARDO V, LECLERCQ B et al.: Sequential therapies for proliferative lupus nephritis. N. Engl. J. Med. (2004) 350: 971-980.
16. MOK CC, HO CT, CHAN KW, LAU CS, WONG RW: Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthritis Rheum. (2002) 46:1003-1013.
17. ABU-SHAKRA M, SHOENFELD Y: Azathioprine therapy for patients with systemic lupus erythematosus. Lupus (2001) 10:152-153.
18. SATO EI: Methotrexate therapy in systemic lupus erythematosus. Lupus (2001) 10:162-164.
19. REMER CF, WEISMAN MH, WALLACE DJ: Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study. Lupus (2001) 10:480-483.
20. HU W, LIU Z, SHEN S et al.: Cyclosporine A in treatment of membranous lupus nephropathy. Chin. Med. J. (2003) 116:1827-1830.
21. DAMMACCO F, DELLA CASA A et al.: Cyclosporine-A plus steroids versus steroids alone in the 12-month treatment of systemic lupus erythematosus. Int. J. Clin. Lab. Res. (2000) 30:67-73.
22. STEINBERG AD, KALTREIDE RHB, STAPLES PJ, GOETZL EJ, TALAL N, DECKER JL: Cyclophosphamide in lupus nephritis: a controlled trial. Ann. Intern. Med. (1971) 75:165-171.
23. HOUSSIAU FA, VASCONCELOS C, D'CRUZ D, et al.: Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. (2002) 46:2121-2131.
24. BROOK CG, EVANS PR: Psychosis in systemic lupus erythematosus (SLE) and the response to cyclophosphamide. Proc. R. Soc. Med. (1969) 62:912.
25. FLANC RS, ROBERTS MA, STRIPPOLI GF, CHADBAN SJ, KERR PG, ATKINS RC: Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am. J. Kidney Dis. (2004) 43:197-208.
26. MILLER JJ 3RD, WILLIAMS GF, LEISSRING JC: Multiple late complications of therapy with cyclophosphamide, including ovarian destruction. Am. J. Med. (1971) 50:530-535.
27. WECHSLER B, HUONG DU LT, PIETTE JC: Is there a role for antithrombotic therapy in the prevention of pregnancy loss? Haemostasis (1999) 29:S1:112-20.
28. MERRILL JT: Regulation of the vasculature: clues from lupus. Curr. Opin. Rheumatol. 2002) 14:504-509.
29. FABBRI P, CARDINALI C, GIOMI B, CAPRONI M: Cutaneous lupus erythematosus: diagnosis and management. Am. J. Clin. Dermatol. (2003) 4:449-465.
30. TRAYNOR AE, SCHROEDER J, ROSA RM, et al.: Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a Phase I study. Lancet (2000) 356:701-707.
31. HASHIMOTO N, IWASAKI T, SEKIGUCHI M et al.: Autologous hematopoietic stem cell transplantation for refractory antiphospholipid syndrome causing myocardial necrosis. H. Bone Marrow Transplant (2004) 33:863-866.
32. KANG I, PARK SH: Infectious complications in SLE after immunosuppressive therapies. Curr. Opin. Rheumatol. (2003) 15:528-534.
33. BARR RG, SELIGER S, APPEL GB et al.: Prognosis in proliferarive lupus nephritis: the role of socio-economic status and race/ethnicity. Nephrol. Dial. Transplant (2003) 18:2039-2046.
34. CORTES-HERNANDEZ J, ORDI-ROS J, LABRADOR M et al.: Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone. Lupus (2003) 12:287-296.
35. ISENBERG D, LECKIE MJ: Biological treatments for systemic lupus erythematosus. Scand. J. Rheumatol. (2002) 31:187-191.
36. BOGDANOVIC R, NIKOLIC V, PASIC S et al.: Lupus nephritis in childhood: a review of 53 patients followed at a single center. Pediatr. Nephrol. (2004) 19:36-44.
37. ROSENWALD M: No favorite in race to treat lupus the Washington Post (2004) Monday, September 6:E01.
38. ARBUCKLE MR, REICHLIN M, HARLEY JB, JAMES JA: Shared early autoantibody recognition events in the development of anti-Sm B/B' in human lupus. Scand. J. Immunol. (1999) 50:447-455.
39. JAMES JA, HARLEY JB: A model of peptide-induced lupus autoimmune B cell epitope spreading is strain specific and is not H-2 restricted in mice. J. Immunol. (1998) 160:502-508.
40. KIM SJ, GERSHOV D, MA X, BROT N, ELKON KB: Opsonization of apoptotic cells and its effect on macrophage and T cell immune responses. Ann. NY Acad. Sci. (2003) 987:68-78.
41. RAVIRAJAN CT, PITTONI V, ISENBERG DA: Apoptosis in human autoimmune diseases. Int. Rev. Immunol. (1999) 18:563-589. Review of the role of apoptosis in autoimmunity with fundamental implications for SLE.
42. GRODZICKY T, ELKON KB: Apoptosis: a case where too much or too little can lead to autoimmunity. Mt. Sinai. J. Med. (2002) 69:208-219.
43. BAUMLER C, KIM GO, ELKON KB: Growth regulation of activated lymphocytes: defects in homeostasis lead to autoimmunity and/or lymphoma. Rev. Immunogenet. (2000) 2:283-290.
44. KAY MM, GOODMAN J: Immunoregulation of cellular lifespan: physiologic autoantibodies and their peptide antigens. Cell Mol. Biol. (2003) 49:217-243.
45. GARDNER-THORPE J, ITO H, ASHLEY SW, WHANG EE: Autoantibody-mediated inhibition of pancreatic cancer cell growth in an athymic (nude) mouse model. Pancreas (2003) 27:180-189.
46. STAFFORD HA, ANDERSON CJ, REICHLIN M: Unmasking of anti-ribosomal P autoantibodies in healthy individuals. J. Immunol. (1995) 155:2754-2761. Evidence that autoantibodies are found in healthy people, changing the paradigm for SLE pathogenesis from an aberrant immune response to a disregulated one.
47. BOUVET JP, STAHL D, ROSE S, QUAN CP, KAZATCHKINE MD, KAVERI SV: Induction of natural autoantibody activity following treatment of human immunoglobulin with dissociating agents. J. Autoimmun. (2001) 16:163-172.
48. MERRILL JT: Dehydroepiandrosterone, a sex steroid metabolite in development for systemic lupus erythematosus. Expert Opin. Investig. Drugs (2003) 12:1017-1025.
49. PETRI MA, LAHITA RG, VAN VOLLENHOVEN RF et al.: Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. (2002) 46:1820-1829.
50. CHANG DM, LAN JL, LIN HY, LUO SF: Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum. (2002) 46:2924-2927.
51. DING L, ZHAO M, ZOU W, LIU Y, WANG H: Mycophenolate mofetil combined with prednisone for diffuse proliferarive lupus nephritis: a histopathological study. Lupus (2004) 13:113-118.
52. LI L, WANG H, LIN S: Mycophenolate mofetil treatment for diffuse proliferative lupus nephritis: a multicenter clinical trial in China. Zhonghua Nei Ke Za Zhi (2002) 41:476-479 (abstract only: paper nor available).
53. CONTRERAS G, PARDO V, LECLERCQ B et al.: Sequential therapies for proliferative lupus nephritis. N. Engl. J. Med. (2004)350:971-980. Evidence for alternative treatments to cyclophosphamide in lupus nephritis.
54. HARZALLAH K, BADID C, FOUQUE D, LEFRANCOIS N, TOURAINE JL, LAVILLE M: Efficacy of mycophenolate mofetil on recurrent glomerulonephriris after renal transplantation. Clin. Nephrol. (2003) 59:212-216.
55. ZHAO M, CHEN X, CHEN Y et al.: Clinical observations of mycophenolate mofetil therapy in refractory primary nephrotic syndrome. Nephrology (2003) 8:2-10.
56. CHAN TM, LI FK, TANG CS et al.: Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N. Engl. J. Med. (2000) 343:1156-1163.
57. MERRILL JT: LJP 1082: a toleragen for Hughes syndrome. Lupus (2004) 13:335-338.
58. WEISMAN MH, BLUESTEIN HG, BERNER CM, DE HAAN HA: Reduction in circulating dsDNA antibody titer arter administration of LJP 394. J. Rheumatol. (1997) 24:314-318. Evidence for a biological effect of Riquent.
59. WALLACE DJ, TUMLIN JA: LJP 394 (abetimus sodium, Riquent) in the management of systemic lupus erythematosus. Lupus (2004) 13:323-327.
60. ALARCON-SEGOVIA D, TUMLIN JA, FURIE RA et al.: LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum. (2003) 48:442-454.
61. SPERTINI F, LEIMGRUBER A, MOREL B et al.: Idiotypic vaccination with a murine anti-dsDNA antibody: Phase I study in patients with nonactive systemic lupus erythematosus with nephritis. J. Rheumatol. (1999) 26:2602-2608.
62. WAISMAN A, RUIZ PJ, ISRAELI E et al.: Modulation of murine systemic lupus erythematosus with peptides based on complementarity determining regions of a pathogenic anti-DNA monoclonal antibody. Proc. Nat. Acad. Sci. (1997) 94(9):4620-4625. Evidence from a murine model supporting the potential use of CR1 peptide in lupus-like disease.
63. DAYAB M, SEGAL R, STHOEGER Z et al.: J. Clin. Immunol. (2000) 20:187-192.
64. GRAMMER AC, SLOTA R, FISCHER R et al.: Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J. Clin. Invest. (2003) 112:1506-1520.
65. HARIGAI M, HARA M, FUKASAWA C et al.: Responsiveness of peripheral blood B cells to re-combinant CD40 ligand in patients with systemic lupus erythematosus. Lupus (1999) 8:227-233.
66. UHM WS, NA K, SONG GW et al.: Cytokine balance in kidney tissue from lupus nephritis patients. Rheumatology (2003) 42(8):935-938.
67. KUROIWA T, SCHLIMGEN R, ILLEI GG, BOUMPAS DT: Monocyte response to Th1 stimulation and effector function toward human mesangial cells are not impaired in patients with lupus nephritis. Clin. Immunol. (2003) 106:65-72.
68. KATO K, SANTANA-SAHAGUN E, RASSENTI LZ et al.: The soluble CD40 ligand sCD154 in systemic lupus erythematosus. J. Clin. Invest. (1999) 104:947-955.
69. HIGUCHI T, AIBA Y, NOMURA T et al.: Cutting edge: ectopic expression of CD40 ligand on B cells induces lupus-like autoimmune disease. J. Immunol. (2002) 168:9-12.
70. QUEZADA SA, ECKERT M, ADEYI OA, SCHNED AR, NOELLE RJ, BURNS CM: Distinct mechanisms of action of ami-CD154 in early versus late treatment of murine lupus nephritis. Arthritis. Rheum. (2003) 48:2541-2554.
71. KAIRAITIS L, WANG Y, ZHENG L, TAY YC, WANG Y, HARRIS DC: Blockade of CD40-CD40 ligand protects against renal injury in chronic proteinuric renal disease. Kidney Int. (2003) 64:1265-1272.
72. WANG X, HUANG W, SCHIFFER LE, MIHARA M, AKKERMAN A, HIROMATSU K, DAVIDSON A: Effects of anti-CD 154 treatment on B cells in murine systemic lupus erythematosus. Arthritis Rheum. (2003) 48:495-506.
73. KALLED SL, CUTLER AH, BURKLY LC: Apoptosis and altered dendritic cell homeostasis in lupus nephritis are limited by anti-CD154 treatment. J. Immunol. (2001) 167:1740-1747.
74. BRAMS P, BLACK A, PADLAN EA et al.: A humanized anti-human CD154 monoclonal antibody blocks CD154-CD40 mediated human B cell activation. Int. Immunopharmacol. (2001) 1:277-294.
75. HUANG W, SINHA J, NEWMAN J et al.: The effect of anti-CD40 ligand antibody on B cells in human systemic lupus erythematosus. Arthritis Rheum. (2002) 46:1554-1562.
76. DAVIS JC JR, TOTORITIS MC, ROSENBERG J, SKLENAR TA, WOFSY D: Phase 1 clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J. Rheumatol. (2001) 28:95-101.
77. KALUNIAN KC, DAVIS JC JR, MERRILL JT, TOTORITIS MC, WOFSY D: Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. (2002) 46:3251-3258.
78. BOUMPAS DT, FURIE R, MANZI S et al.: A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis Arthritis Rheum. (2003) 48:719-727.
79. STOHL W, METYAS S, TAN SM et al.: B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum. (2003) 48:3475-3486.
80. STOHL W: SLE-systemic lupus erythematosus: a BLySful, yet BAFFling, disorder. Arthritis Res. Ther. (2003) 5:136-138.
81. KAWASAKI A, TSUCHIYA N, FUKAZAWA T, HASHIMOTO H, TOKUNAGA K: Analysis on the association of human BLYS (BAFF, TNFSF13B) polymorphisms with systemic lupus erythematosus and rheumatoid arthritis. Genes Immun. (2002) 3:424-429.
82. ROSCHKE V, SOSNOVTSEVA S, WARD CD et al.: BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J. Immunol. (2002) 169:4314-4321.
83. SESHASAYEE D, VALDEZ P, YAN M, DIXIT VM, TUMAS D, GREWAL IS: Loss of TACI causes fatal lymphoproliferarion and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity (2003) 18:279-288.
84. BAKER KP, EDWARDS BM, MAIN SH et al.: Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum. (2003) 483:253-265. Characterisation of LymphoStat-B.
85. LEANDRO MJ, EDWARDS JC, CAMBRIDGE G, EHRENSTEIN MR, ISENBERG DA: An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. (2002) 46(10):2673-2677.
86. ANOLIK JH, CAMPBELL D, FELGAR RE, et al.: The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. (2003) 48:455-459.
87. WEIDE R, HEYMANNS J, PANDOR FA, KOPPLER H: Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapy. Lupus (2003) 12:779-782.
88. ANOLIK J, SANZ I, LOONEY RJ: B cell depletion therapy in systemic lupus erythematosus. Curr. Rheumatol. Rep. (2003) 5:350-356.
89. LOONEY RJ, ANOLIK JH, CAMPBELL D et al.: B cell depletion as a novel treatment for systemic lupus erythematosus: a Phase I/II does-escalation trial of rituximab. Arthritis Rheum. (2002) 50: 2580-2589. Phase I/II study of rituximab in SLE.
90. KNEITZ C, WILHELM M, TONY HP: Effective B cell depletion with rituximab in the treatment of autoimmune diseases. Immunobiology (2002) 206:519-527.
91. SHANAFELT TD, MADUEME HL, WOLF RC, TEFFERI A: Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. Mayo. Clin. Proc. (2003) 78:1340-1346.
92. ZAJA F, VIANELLI N SPEROTTO A, DE VITA S, et al.: B-cell compartment as the selective target for the treatment of immune thrombocytopenias. Haematologica (2003) 88:538-546.
93. CATE R SMIERS FJ, BREDIUS RG, LANKESTER AC, et al.: Anti-CD20 monoclonal antibody (rituximab) for refractory autoimmune thrombocytopenia in a girl with systemic lupus erythematosus Rheumatology (2004) 43:244.
94. SAITO K, NAWATA M, NAKAYAMADA S, TOKUNAGA M, TSUKADA J, TANAKA Y: Successful treatment with anti-CD20 monoclonal antibody (rituximab) of life-threatening refractory systemic lupus erythematosus with renal and central nervous system involvement. Lupus (2003) 12:798-800.
95. FRA GP, AVANZI GC, BARTOLI E: Remission of refractory lupus nephritis with a protocol including rituximab. Lupus (2003) 12:783-787.
96. GLADMAN DD: Indicators of disease activity, prognosis, and treatment of systemic lupus erythematosus. Wellesley Hospital, Toronto, Ontario, Canada. Curr. Opin. Rheumatol. (1994) 6(5):487-492.
97. GLADMAN DD, GOLDSMITH CH, UROWITZ MB et al.: Sensitivity to change of 3 Systemic Lupus Erythematosus Disease Activity Indices: international validation. J. Rheumatol. (1994) 21:1468-1471.
98. HAY EM, BACON PA, GORDON C et al.: The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q. J. Med. (1993) 86:447-458. Description and study of the BILAG instrument for measuring disease activity in SLE.
99. GLADMAN DD, GOLDSMITH CH, UROWITZ MB et al.: Crosscultural validation and reliability of 3 disease activity indices in systemic lupus erythematosus. J. Rheumatol. (1992) 19:608-611.
100. BENCIVELLI W, VITALI C, ISENBERG DA et al.: Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Clin. Exp. Rheumatol. (1992) 10:549-554.
101. WARD MM, MARX AS, BARRY NN: Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus. Medical Service, VA Palo Alto Health Care System, CA 94304, USA. J. Rheumatol. (2000) 27:664-670.
102. CORZILLIUS M, FORTIN P, STUCKI G: Responsiveness and sensitivity to change of SLE disease activity measures. Lupus (1999) 8:655-659.